Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma

Abalı, Hüseyin; Ürün, Yüksel; Öksüzoğlu, Berna; Budakoğlu, Burçin; Yıldırım, Nuriye; Güler, Tunç; Özet, Gülsüm; Zengi̇n, Nurullah

doi:10.1080/07357900701788098

Cited by 42 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ICE seems to have higher rates of response than DHAP regimen as in DHAP group 11 (22.5%) achieved CR and 17 (35%) achieved PR, leading to an overall response rate (ORR: CR + PR) of 57.5%. In the evaluable ICE group (n = 22) rates of CR, PR, and ORR were 27%, 41% and 68% and in the DHAP group (n = 27) rates of CR, PR, and ORR were 18%, 30% and 48% (P = 0.24, for ORR) 9 .…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine, Dexamethasone, and Cisplatin (GDP) versus Dexamethasone,Cytarabine, and Cisplatin (DHAP) as Salvage Chemotherapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Ismaeil

Tarek

Mohamed

et al. 2013

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

IntroductIonNon Hodgkin lymphomas (NHLs) are the most commonly occurring hematologic malignancies in the United States. They represent 4% to 5% of all new cancer cases. There is 65,540 men and women (35,380 men and 30,160 women) ARM I "cisplatin 75mg/m2 on day 1, dexamethasone 40 mg on days 1-4, and gemcitabine 1000mg/m2 on days 1 and 8, given every 21 days" and ARM II, Patients received "cisplatin 75mg/m2 IV over 24 hours on day 1, dexamethasone as in arm A, and cytarabine 2gm/m2 IV over 3 hours every 12 hours on day 2, given every 21 days". A total of 330 chemotherapy cycles were administered, with a mean of 5.4 cycles per patient (range 2-6). results: Among the sixty two eligible patients treated, there were three early deaths, including one patient in group A and two patient in group B. Four patients in group A and three patients in group B had disease progression during treatment. The overall response rate was 65% (29% CR rate, 38% PR rate) in arm A and 67.6% (32.2% CR rate, 35.4% PR rate) in arm B. The median disease free survival time was 10 months, 9 months (95% CI, 6.078 to 11.922 months), the median Progression free survival time was 4 months (95% CI, 2.108 to 5.892 months), 4 months (95% CI, 3.028 to 4.972 months), the median overall survival time was 20 months (95% CI, 14.377 to 25.623 months), 21 months (95% CI, 9.352 to 32.648 months) for arm A& B, respectively. Hematologic toxicities were comparable between the two arms with greater number of patients developed grade III, IV neutropenia in arm B. The most common grade III or IV hematological toxicities were neutropenia and thrombocytopenia, neutopenia was 62.9% in group A and 70% in group B, febrile neutopenia was significantly higher in group B (53.8%) compared to (22.2%) in group A. Grade III or IV thrombocytopenia was observed in 29.7% among both groups. Other hematological toxicities are comparable in both groups. Stomatitis and infection were higher in arm B. Stomatitis was 36%, 69.2%, Infection was 24%, 42.3% for arm A& B, respectively. conclusion: The study revealed no significant differences between GDP and DHAP as regarding response rate, OS, DFS and PFS in treatment of relapsed or refractory DLBCL. Toxicity was higher in DHAP group.

show abstract

Section: Discussionmentioning

confidence: 99%

Gemcitabine, Dexamethasone, and Cisplatin (GDP) versus Dexamethasone,Cytarabine, and Cisplatin (DHAP) as Salvage Chemotherapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Ismaeil

Tarek

Mohamed

et al. 2013

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

show abstract

“…В качестве предтрансплантационной индукци-онной подготовки большинство авторов рекомендуют схемы DHAP, IGEV, ICE, ASHAP, ESHAP, GDP, Dexa-BEAM, mini-BEAM и др., обладающие сопоставимой эффек-тивностью [13][14][15][16][17][18][19][20][21].…”

Section: Introductionunclassified

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

Мочкин

Саржевский

Dubinina

et al. 2018

Клиническая онкогематология

View full text Add to dashboard Cite

Aim. To estimate the long-term outcome of the programmed treatment of classical Hodgkin's lymphoma (cHL) including high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) as well as the effect of various factors on the achieved results in a singlecenter study. Materials & Methods. In the A.A. Maksimov Clinical Center of Hematology and Cellular Therapy of the NI Pirogov Russian National Medical Center of Surgery 260 cHL patients received HDCT combined with auto-HSCT within the period from December 2006 to March 2017. The median age was 29 years (range 17-62). The study included 40 % men (п = 104), and 60 % women (п = 156). The median pretransplantation chemotherapy line was 3 (range 2-9). At this stage, prior to auto-HSCT, complete remission (CR) rate was 26.5 %, partial remission (PR) rate was 52.3 %, disease stabilisation rate was 13.5 %. HDCT with auto-HSCT was applied beyond progression as a salvage therapy in 7.7 % of patients. In 79.6 % of patients the standard BEAM and CBV conditioning regimens were used. Results. After HDCT combined with auto-HSCT overall 5-year survival (OS) of 260 cHL patients was 74 %, and 5-year progression-free survival (PFS) was 48 %, which corresponds to the results of some international studies. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during the first CR or PR (85 %) vs the second and subsequent CR and PR (71 %). Neither gender (p = 0.4) nor ECOG status (p = 0.2) effects on OS and PFS were revealed. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during CR or PR (82 %) vs disease stabilisation and progression (54 %) as well as upon achieving CR (93 %) vs PR (77 %). Conclusion. In cHL tumor sensitivity to chemotherapy is the essential indication for HDCT combined with auto-HSCT. The optimal time for HDCT and auto-HSCT in cHL is the first CR/PR, and the best treatment outcome is achieved in patients with complete response prior to HDCT and auto-HSCT.

show abstract

“…В качестве предтрансплантационной подготов-ки большинство авторов рекомендуют схемы DHAP, IGEV, ICE, ASHAP, ESHAP, GDP, DexaBEAM, miniBEAM и др., обладающие сопоставимой эффек-тивностью [17][18][19][20][21][22][23][24][25].…”

Section: Introductionunclassified

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. 10 years’ experience of the N.I. Pirogov National Medical and Surgical Center Ministry of Health of Russia

Мочкин¹,

Sarzhevskiy²,

Dubinina³

et al. 2017

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma

Abstract: Although the toxicity profiles of both ICE and DHAP regimens were similar in the treatment of patients with relapsed or refractory HD or NHL, ICE seems to have higher rates of response than DHAP regimen does.

Cited by 42 publications

References 30 publications

Gemcitabine, Dexamethasone, and Cisplatin (GDP) versus Dexamethasone,Cytarabine, and Cisplatin (DHAP) as Salvage Chemotherapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Gemcitabine, Dexamethasone, and Cisplatin (GDP) versus Dexamethasone,Cytarabine, and Cisplatin (DHAP) as Salvage Chemotherapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. 10 years’ experience of the N.I. Pirogov National Medical and Surgical Center Ministry of Health of Russia

Contact Info

Product

Resources

About